- Assistant Professor, Medicine - (Clinical Scholar Track)
- M. S. Ramaiah Medical College, Bangalore, India
- University of Arizona, Tucson, Arizona (2014 - Ongoing)
- University of Arizona, Tucson, Arizona (2008 - 2011)
Licensure & Certification
- ABIM IM (2008)
- ABIM Pulmonary (2015)
- ABIM Critical Care (2018)
Interventional PulmonologyILDCritical CareTransplant Pulmonology
No activities entered.
- Casanova, N. G., Gonzalez-Garay, M. L., Sun, B., Bime, C., Sun, X., Knox, K. S., Crouser, E. D., Sammani, N., Gonzales, T., Natt, B., Chaudhary, S., Lussier, Y., & Garcia, J. G. (2020). Differential transcriptomics in sarcoidosis lung and lymph node granulomas with comparisons to pathogen-specific granulomas. Respiratory research, 21(1), 321.More infoDespite the availability of multi-"omics" strategies, insights into the etiology and pathogenesis of sarcoidosis have been elusive. This is partly due to the lack of reliable preclinical models and a paucity of validated biomarkers. As granulomas are a key feature of sarcoidosis, we speculate that direct genomic interrogation of sarcoid tissues, may lead to identification of dysregulated gene pathways or biomarker signatures.
- Chaudhary, S., Natt, B., Bime, C., Knox, K. S., & Glassberg, M. K. (2020). Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused. Frontiers in medicine, 7, 539.More infoAfter decades of research, two therapies for chronic fibrotic lung disease are now approved by the FDA, with dozens more anti-fibrotic therapies in the pipeline. A great deal of enthusiasm has been generated for the use of these drugs, which are by no means curative but clearly have a favorable impact on lung function decline over time. Amidst a flurry of newly developed and repurposed drugs to treat the coronavirus disease 2019 (COVID-19) and its accompanying acute respiratory distress syndrome (ARDS), few have emerged as effective. Historically, survivors of severe viral pneumonia and related acute lung injury with ARDS often have near full recovery of lung function. While the pathological findings of the lungs of patients with COVID-19 can be diverse, current reports have shown significant lung fibrosis predominantly in autopsy studies. There is growing enthusiasm to study anti-fibrotic therapy for inevitable lung fibrosis, and clinical trials are underway using currently FDA-approved anti-fibrotic therapies. Given the relatively favorable outcomes of survivors of virus-mediated ARDS and the low prevalence of clinically meaningful lung fibrosis in survivors, this perspective examines if there is a rationale for testing these repurposed antifibrotic agents in COVID-19-associated lung disease.
- Graney, B. A., He, C., Marll, M., Matson, S., Bianchi, P., Cosgrove, G. P., Lee, J. S., & , P. C. (2020). Essential Components of an Interstitial Lung Disease Clinic: Results From a Delphi Survey and Patient Focus Group Analysis. Chest.More infoManagement of patients with interstitial lung disease (ILD) requires subspecialized, comprehensive, multidisciplinary care. The Pulmonary Fibrosis Foundation established the Care Center Network (CCN) in 2013 with identified criteria to become a designated CCN site. Despite these criteria, the essential components of an ILD clinic remain unknown.
- Ripperger, T. J., Uhrlaub, J. L., Watanabe, M., Wong, R., Castaneda, Y., Pizzato, H. A., Thompson, M. R., Bradshaw, C., Weinkauf, C. C., Bime, C., Erickson, H. L., Knox, K., Bixby, B., Parthasarathy, S., Chaudhary, S., Natt, B., Cristan, E., Aini, T. E., Rischard, F., , Campion, J., et al. (2020). Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure. medRxiv : the preprint server for health sciences.More infoWe conducted an extensive serological study to quantify population-level exposure and define correlates of immunity against SARS-CoV-2. We found that relative to mild COVID-19 cases, individuals with severe disease exhibited elevated authentic virus-neutralizing titers and antibody levels against nucleocapsid (N) and the receptor binding domain (RBD) and the S2 region of spike protein. Unlike disease severity, age and sex played lesser roles in serological responses. All cases, including asymptomatic individuals, seroconverted by 2 weeks post-PCR confirmation. RBD- and S2-specific and neutralizing antibody titers remained elevated and stable for at least 2-3 months post-onset, whereas those against N were more variable with rapid declines in many samples. Testing of 5882 self-recruited members of the local community demonstrated that 1.24% of individuals showed antibody reactivity to RBD. However, 18% (13/73) of these putative seropositive samples failed to neutralize authentic SARS-CoV-2 virus. Each of the neutralizing, but only 1 of the non-neutralizing samples, also displayed potent reactivity to S2. Thus, inclusion of multiple independent assays markedly improved the accuracy of antibody tests in low seroprevalence communities and revealed differences in antibody kinetics depending on the viral antigen. In contrast to other reports, we conclude that immunity is durable for at least several months after SARS-CoV-2 infection.
- Ripperger, T. J., Uhrlaub, J. L., Watanabe, M., Wong, R., Castaneda, Y., Pizzato, H. A., Thompson, M. R., Bradshaw, C., Weinkauf, C. C., Bime, C., Erickson, H. L., Knox, K., Bixby, B., Parthasarathy, S., Chaudhary, S., Natt, B., Cristan, E., El Aini, T., Rischard, F., , Campion, J., et al. (2020). Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Immunity, 53(5), 925-933.e4.More infoWe conducted a serological study to define correlates of immunity against SARS-CoV-2. Compared to those with mild coronavirus disease 2019 (COVID-19) cases, individuals with severe disease exhibited elevated virus-neutralizing titers and antibodies against the nucleocapsid (N) and the receptor binding domain (RBD) of the spike protein. Age and sex played lesser roles. All cases, including asymptomatic individuals, seroconverted by 2 weeks after PCR confirmation. Spike RBD and S2 and neutralizing antibodies remained detectable through 5-7 months after onset, whereas α-N titers diminished. Testing 5,882 members of the local community revealed only 1 sample with seroreactivity to both RBD and S2 that lacked neutralizing antibodies. This fidelity could not be achieved with either RBD or S2 alone. Thus, inclusion of multiple independent assays improved the accuracy of antibody tests in low-seroprevalence communities and revealed differences in antibody kinetics depending on the antigen. We conclude that neutralizing antibodies are stably produced for at least 5-7 months after SARS-CoV-2 infection.
- Chaudhary, S., Meinke, L., Ateeli, H., Knox, K. S., Raz, Y., & Ampel, N. M. (2017). Coccidioidomycosis among persons undergoing lung transplantation in the coccidioidal endemic region. Transplant infectious disease : an official journal of the Transplantation Society, 19(4).More infoCoccidioidomycosis, an endemic fungal infection, is more likely to be symptomatic and severe among those receiving allogeneic transplants. While several case series have been published for various transplanted organs, none has described the incidence and outcomes in those receiving lung transplants within the coccidioidal endemic region.
- Chaudhary, S. (2016). Bronchial Artery Embolization. Southwest Journal of Pulmonary and Critical Care.
- Jarrett, B., Ghazala, S., Chao, J., & Chaudhary, S. (2016). Case of Steven-Johnson Syndrome in a male with breast cancer secondary to docetaxel/cyclophosphamide therapy. BMJ case reports, 2016.More infoThe mortality rate for Stevens-Johnson syndrome (SJS) is estimated to be ∼12% and for toxic epidermal necrolysis (TEN) it is around 30%. It continues to be a severe life-threatening drug reaction. We present a 60-year-old Caucasian man with a medical history significant for breast cancer status post mastectomy and chemotherapy with docetaxel and cyclophosphamide who presented with severe mucositis and a progressing skin rash consistent with SJS. He was started on high-dose corticosteroids and IVIG but continued to have worsening mucosal ulcerations and severe bleeding from the oral, conjunctival and genital mucosa. He underwent several rounds of plasmapheresis and additional high-dose steroids with mild improvement in the mucocutaneous manifestations. He subsequently developed respiratory failure, which required mechanical ventilation, as well as disseminated intravascular coagulation, diffuse alveolar haemorrhage, with Pneumocystis jirovecii pneumonia which led to his demise on hospital day 15.
- Wong, C., Fernandes, A., Huang, J., & Chaudhary, S. (2015). Medical image of the week: ascaris lumbridoies. Southwest Journal of Pulmonary Critical Care.
- Chaudhary, S. (2010). Coccidioidomycosis in Lung Transplant Recipients in an Endemic Area. Chest.
- Chaudhary, S., Knox, K. S., Raz, Y., & Meinke, L. E. (2010). Coccidioidomycosis in Lung Transplant Recipients in an Endemic Area. American College of Chest Physicians.
- Poojary, I., Meinke, L. E., & Chaudhary, S. (2011, January/Winter). Pulmonary Arterial Hypertension When Seen in HIV Clinical Case Puzzlers. CHEST. Honolulu, HI.
- Chaudhary, S., Knox, K. S., Raz, Y., & Meinke, L. E. (2010, October/Fall). Coccidioidomycosis in Thoracic Transplants. Infectious Disease Conference at the University of Arizona. Tucson, AZ.
- Chaudhary, S., & Goldman, J. (2006, May/Spring). Myxedema Coma. American College of Physicians Chapter Meeting. Troy, MI.
- Ahmad, K., & Chaudhary, S. (2015, May/Spring). Recurrent Diffuse Alveolar Hemorrhage Induced By Hepatitis C Associated Mixed Cryoglobulinemia. American Thoracic Society. Denver, CO.
- Chaudhary, S., Goldschmid, M., & Szerlip, H. (2010, September/Fall). Riding out of the storm: treatment of Thyroid storm. American College of Physicians Meeting Arizona Chapter. Phoenix, AZ.
- Nagaraja, V., Underwood, S., Munagala, P., Chaudhary, S., Potharaju, A., & Szerlip, H. (2010, September/Fall). Interns' acquaintance to the system, poster presentation. American College of Physicians Arizona Chapter Annual Meeting. Phoenix, AZ.
- Doraiswamy, V., Nagaraja, V., Chaudhary, S., & Goldschmid, M. (2008, October/Fall). Middle aged man with altered Mental Status, severe Metabolic Acidosis and Acute Renal Failure. American College of Physicians Arizona Chapter.
- Nagaraja, V., Doraiswamy, V., Bucknor, Y., Chaudhary, S., Answer, F., & Goldschmid, M. (2008, October/Fall). Thyroid storm and coma-an atypical presentation, poster presentation. American College of Physicians Arizona Chapter.
- Chaudhary, S., Grandhi, J., & Goldman, J. (2007, March/Spring). Thyrotoxic Hypokalemic Periodic Paralysis. Annual Research Day at Synergy Medical Education Alliance. Saginaw, MI.
- Chaudhary, S., Talati, S., Khan, U., & Kogulan, P. (2007, May/Spring). A Unique Case of Posterior Reversible Encephalopathy Syndrome (PRES). Annual Research Day at Synergy Medical Education Alliance. Saginaw, MI.